---
title: "Wolwo Pharma released its 2024 annual performance, with a net profit attributable to the parent company of 318 million yuan, an increase of 2.46%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/236582524.md"
description: "Wolwo Pharma released its 2024 annual report, with operating revenue of 925 million yuan, a year-on-year increase of 9.10%; net profit attributable to the parent company of 318 million yuan, a year-on-year increase of 2.46%; and net profit excluding non-recurring gains and losses of 306 million yuan, a year-on-year increase of 2.72%. The basic earnings per share are 0.607 yuan, and it plans to distribute a cash dividend of 1.20 yuan (tax included) for every 10 shares to all shareholders"
datetime: "2025-04-18T12:07:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/236582524.md)
  - [en](https://longbridge.com/en/news/236582524.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/236582524.md)
---

# Wolwo Pharma released its 2024 annual performance, with a net profit attributable to the parent company of 318 million yuan, an increase of 2.46%

According to the Zhitong Finance APP, Wolwo Pharma (300357.SZ) released its annual report for 2024, reporting an operating income of 925 million yuan, a year-on-year increase of 9.10%. The net profit attributable to shareholders of the listed company was 318 million yuan, a year-on-year increase of 2.46%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 306 million yuan, a year-on-year increase of 2.72%. The basic earnings per share were 0.607 yuan. In addition, it plans to distribute a cash dividend of 1.20 yuan (including tax) for every 10 shares to all shareholders

### Related Stocks

- [300357.CN](https://longbridge.com/en/quote/300357.CN.md)

## Related News & Research

- [PRECIOUS-Treasury yields, dollar weigh on gold amid inflation concerns](https://longbridge.com/en/news/286929968.md)
- [PTA-DD: Warimpex Finanz- und Beteiligungs AG: Correction of a Managers' transactions announcement according to article 19 MAR from 19.05.2026](https://longbridge.com/en/news/287058272.md)
- [Phase 3-ready cancer biotech Parabilis Medicines files for a $100 million IPO](https://longbridge.com/en/news/286972125.md)
- [Motiva Port Arthur refinery reports crude oil release after pipe issues](https://longbridge.com/en/news/286971029.md)
- [New York Governor Signs Bills To Preserve Mandatory Vaccines](https://longbridge.com/en/news/286947583.md)